ATE308538T1 - Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen - Google Patents

Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen

Info

Publication number
ATE308538T1
ATE308538T1 AT00927199T AT00927199T ATE308538T1 AT E308538 T1 ATE308538 T1 AT E308538T1 AT 00927199 T AT00927199 T AT 00927199T AT 00927199 T AT00927199 T AT 00927199T AT E308538 T1 ATE308538 T1 AT E308538T1
Authority
AT
Austria
Prior art keywords
adrenergic receptor
receptor antagonists
sexual disorders
selective alpha
treat sexual
Prior art date
Application number
AT00927199T
Other languages
English (en)
Inventor
Amedeo Leonardi
Gianni Motta
Rodolfo Testa
Giorgio Sironi
Original Assignee
Recordati Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ireland Ltd filed Critical Recordati Ireland Ltd
Application granted granted Critical
Publication of ATE308538T1 publication Critical patent/ATE308538T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
AT00927199T 1999-05-07 2000-05-08 Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen ATE308538T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000995A IT1312310B1 (it) 1999-05-07 1999-05-07 Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
PCT/EP2000/004308 WO2000067735A2 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
ATE308538T1 true ATE308538T1 (de) 2005-11-15

Family

ID=11382912

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00927199T ATE308538T1 (de) 1999-05-07 2000-05-08 Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen

Country Status (25)

Country Link
US (2) US6303606B1 (de)
EP (1) EP1177190B1 (de)
JP (1) JP2002544158A (de)
KR (1) KR100696755B1 (de)
CN (1) CN1150187C (de)
AT (1) ATE308538T1 (de)
AU (1) AU765487B2 (de)
BR (1) BR0010348A (de)
CA (1) CA2366201A1 (de)
DE (1) DE60023686T2 (de)
DK (1) DK1177190T3 (de)
ES (1) ES2250130T3 (de)
HK (1) HK1039900B (de)
HU (1) HUP0201184A3 (de)
IL (1) IL146003A0 (de)
IT (1) IT1312310B1 (de)
MX (1) MXPA01011261A (de)
NO (1) NO321841B1 (de)
NZ (1) NZ515240A (de)
PL (1) PL196708B1 (de)
RU (1) RU2239633C2 (de)
SI (1) SI1177190T1 (de)
TW (1) TWI224503B (de)
WO (1) WO2000067735A2 (de)
ZA (1) ZA200110042B (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
CA2538415A1 (en) * 2003-09-15 2005-03-24 Wilfred Wayne Lautt Use of antagonists of hepatic sympathetic nerve activity
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
WO2005112889A2 (en) * 2004-05-20 2005-12-01 Recordati Ireland Limited Transmucosal delivery formulations
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
CA2583332C (en) * 2004-10-18 2013-10-01 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle production and therapeutically use of said composition
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2056797A2 (de) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH System mit kontrollierter freisetzung und verfahren zu seiner herstellung
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
CN101592613B (zh) * 2009-07-06 2011-12-21 广东省药品检验所 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法
KR101944552B1 (ko) * 2010-09-13 2019-01-31 오쓰까 세이야꾸 가부시키가이샤 세로토닌, 노르에피네프린 또는 도파민의 감소된 신경전달에 의해 야기된 장애의 치료 또는 예방용 헤테로시클릭 화합물
JP6415982B2 (ja) * 2012-03-12 2018-10-31 大塚製薬株式会社 複素環化合物
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (de) 2012-06-04 2017-02-22 Diamedica Inc. Kallikrein-1-glycosylierungsisoformen aus menschlichem gewebe
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
EP3939591A1 (de) 2016-06-27 2022-01-19 Achillion Pharmaceuticals, Inc. Chinazolin- und indolverbindungen zur behandlung von medizinischen leiden
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW213903B (de) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
EP0611248B1 (de) 1993-02-10 2000-03-22 B.M.R.A. Corporation B.V. Zubereitungen zur Behandlung von Impotenz, die ein Alpha-1 inhibitor und ein Alpha-2 inhibitor enthalten
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
IT1270993B (it) 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
JPH11512710A (ja) 1995-09-29 1999-11-02 メルク エンド カンパニー インコーポレーテッド アルファ１ｂアドレナリンレセプターアンタゴニスト
US5700364A (en) 1995-10-30 1997-12-23 Merck & Co., Inc. Electrochemical oxidation
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP2003525845A (ja) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
HK1039900B (en) 2006-02-03
IT1312310B1 (it) 2002-04-15
KR20020002494A (ko) 2002-01-09
KR100696755B1 (ko) 2007-03-19
NZ515240A (en) 2003-09-26
HUP0201184A2 (en) 2002-10-28
ZA200110042B (en) 2002-07-02
MXPA01011261A (es) 2002-08-12
DE60023686D1 (de) 2005-12-08
NO321841B1 (no) 2006-07-10
NO20015428D0 (no) 2001-11-06
HUP0201184A3 (en) 2003-05-28
WO2000067735A3 (en) 2001-02-01
US20020161009A1 (en) 2002-10-31
DK1177190T3 (da) 2006-02-20
AU765487B2 (en) 2003-09-18
AU4565400A (en) 2000-11-21
RU2239633C2 (ru) 2004-11-10
NO20015428L (no) 2001-11-06
HK1039900A1 (en) 2002-05-17
IL146003A0 (en) 2002-07-25
SI1177190T1 (sl) 2006-02-28
US6953800B2 (en) 2005-10-11
WO2000067735A2 (en) 2000-11-16
ITMI990995A1 (it) 2000-11-07
JP2002544158A (ja) 2002-12-24
ES2250130T3 (es) 2006-04-16
TWI224503B (en) 2004-12-01
EP1177190B1 (de) 2005-11-02
US6303606B1 (en) 2001-10-16
CN1150187C (zh) 2004-05-19
EP1177190A2 (de) 2002-02-06
CA2366201A1 (en) 2000-11-16
PL351624A1 (en) 2003-05-19
BR0010348A (pt) 2002-02-13
CN1354749A (zh) 2002-06-19
DE60023686T2 (de) 2006-07-20
PL196708B1 (pl) 2008-01-31

Similar Documents

Publication Publication Date Title
ATE308538T1 (de) Verwendung von selektiven alpha-adrenergischen rezeptorantagonisten zur behandlung sexueller störungen
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
HUP9802678A2 (hu) Biciklusos aminszármazékok és ezeket tartalmazó PGD2 antagonista hatású készítmények
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60122767D1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE245650T1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
TNSN01100A1 (fr) Derives de glutaramide a substituant cyclopentyle, procede pour leur preparation et compositions les contenant
ATE303804T1 (de) Behandlung von sexueller funktionsstörung mit bombesin rezeptor antagonisten
EA200200132A1 (ru) СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА iGluRДЛЯ ЛЕЧЕНИЯ МИГРЕНИ
ATE363474T1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
ATE255094T1 (de) Piperazinderivate zur behandlung der niedrigen harnwege
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
AR021502A1 (es) Uso de derivados de azabicicloalcanos n-sustituidos para el tratamiento de enfermedades del sistema central nervioso
MXPA03003481A (es) Tratamiento de disfuncion sexual utilizando antagonista de bombesina.
MY139385A (en) Benzimidazoles that are useful in treating sexual dysfunction
MY139582A (en) Benzimidazoles that are useful in treating sexual dysfunction
ATE327235T1 (de) 1,2,5,10-tetrahydropyridazino 4,5-böchinolin-1, 0-dione und ihre anwendung in der behandlung von schmerzen
ATA80042000A (de) Verwendung von beta-2-sympathomimetika und spasmolytika sowie orale zubereitung zur behandlung von erektiler dysfunktion

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1177190

Country of ref document: EP

REN Ceased due to non-payment of the annual fee